• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Who Responds to SSRIs in PTSD?
RESEARCH UPDATE

Who Responds to SSRIs in PTSD?

October 30, 2022
Richard Moldawsky, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

REVIEW OF: Nøhr AK et al, Psychiatry Res 2021;301:113964

STUDY TYPE: Secondary analysis of a controlled trial

SSRIs are often used in PTSD, but it is not clear that they work for all kinds of trauma. Trials of SSRIs are generally positive in women and people with a history of sexual trauma, while trials involving combat-related trauma tend to be negative. The current study aimed to better identify predictors of ­response.

The investigators recruited patients from an ongoing controlled study of 390 patients with PTSD, conducted in 13 countries including the US. Patients were treated open-label with sertraline (100–200 mg/day) or paroxetine (20–40 mg/day) over 12 weeks, these medications being the two SSRIs with FDA approval in PTSD. All patients had experienced a trauma within the past 15 years, including assault with a weapon (31%), death or harm to someone else (21%), sexual assault (13%), or combat or war-zone experience (10%). Just under half had a history of childhood trauma. Ages ranged from 18 to 75, and 62% were female. Symptoms were tracked with the Clinically Administered PTSD Scale (CAPS) along with a patient-rated scale for depression and anxiety. The investigators used a sophisticated statistical technique called growth mixture modeling to attempt to identify predictors of drug response.

The overall response rate was 58.5%, defined as a 30% reduction in the CAPS. Sertraline and paroxetine were equally effective. Sexual assault and female gender were the main predictors of response, including a childhood history of sexual assault. A longer time between the trauma and the treatment also predicted a faster and higher rate of response. Symptoms of depression and anxiety did not predict response to the SSRI. 

One limitation of the study was the exclusion of patients with active suicidality or a history of recent treatment for major depression, anxiety disorders, or substance use disorders. On the one hand, this pure sample reduces the possibility that responses were due to treatment of comorbid disorders. On the other hand, it limits the generalizability of the findings, as does the high dropout rate (40%).

CARLAT TAKE
You can expect to see better response rates to SSRIs when treating PTSD in women and in individuals with a history of sexual trauma. This study confirms that finding, which is pretty consistent across the clinical trials, and adds a little more. Depressive and anxiety symptoms did not predict response, but those with more distant traumas were more likely to respond to SSRIs.


Research Update
KEYWORDS anxiety disorders ptsd research update ssris trauma
    Richard Moldawsky, MD

    Buprenorphine versus Methadone for Prescription Opioid Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: October 30, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Does Abortion Lead to Psychiatric Issues?
    The Enduring Value of Talking Therapy
    Trichotillomania: Diagnosis and Treatment
    Side Effects in Depression
    Who Responds to SSRIs in PTSD?
    CME Post-Test, Psychotherapy, TCPR, December 2022
    DOWNLOAD NOW
    Featured Book
    • HospPsychiatry_Spiral_Binding_Sm.png

      Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

      This comprehensive guide is designed to be a valuable resource for professionals working in...
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.